Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B cell-derived lymphoma entity accounting for ≈5% of all Hodgkin lymphoma (HL) cases. In recent decades, patients with newly diagnosed NLPHL have usually been treated very similarly to classical HL (cHL). The 10-year overall survival...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/13/3310 |
| _version_ | 1797592104024670208 |
|---|---|
| author | Dennis A. Eichenauer Michael Fuchs |
| author_facet | Dennis A. Eichenauer Michael Fuchs |
| author_sort | Dennis A. Eichenauer |
| collection | DOAJ |
| description | Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B cell-derived lymphoma entity accounting for ≈5% of all Hodgkin lymphoma (HL) cases. In recent decades, patients with newly diagnosed NLPHL have usually been treated very similarly to classical HL (cHL). The 10-year overall survival rates with HL-directed approaches are in excess of 90%. However, pathological and clinical characteristics of NLPHL resemble indolent B-cell non-Hodgkin lymphoma (B-NHL) in some aspects. Thus, nodular lymphocyte-predominant B-cell lymphoma has been proposed as an alternative name, and the use of B-NHL-directed treatment strategies has become more common in NLPHL despite limited data. Given the often indolent clinical course of NLPHL, even in the case of relapse, the majority of patients with disease recurrence do not require high-dose chemotherapy and autologous stem cell transplantation but are treated sufficiently with low-intensity approaches such as single-agent anti-CD20 antibody treatment. The establishment of novel prognostic scores for NLPHL patients may optimize risk group and treatment allocation in newly diagnosed and relapsed disease. |
| first_indexed | 2024-03-11T01:46:41Z |
| format | Article |
| id | doaj.art-fed0cbd5dae74c31a6296a6a5955d6f6 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T01:46:41Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-fed0cbd5dae74c31a6296a6a5955d6f62023-11-18T16:15:08ZengMDPI AGCancers2072-66942023-06-011513331010.3390/cancers15133310Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?Dennis A. Eichenauer0Michael Fuchs1First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, D-50937 Cologne, GermanyFirst Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, D-50937 Cologne, GermanyNodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B cell-derived lymphoma entity accounting for ≈5% of all Hodgkin lymphoma (HL) cases. In recent decades, patients with newly diagnosed NLPHL have usually been treated very similarly to classical HL (cHL). The 10-year overall survival rates with HL-directed approaches are in excess of 90%. However, pathological and clinical characteristics of NLPHL resemble indolent B-cell non-Hodgkin lymphoma (B-NHL) in some aspects. Thus, nodular lymphocyte-predominant B-cell lymphoma has been proposed as an alternative name, and the use of B-NHL-directed treatment strategies has become more common in NLPHL despite limited data. Given the often indolent clinical course of NLPHL, even in the case of relapse, the majority of patients with disease recurrence do not require high-dose chemotherapy and autologous stem cell transplantation but are treated sufficiently with low-intensity approaches such as single-agent anti-CD20 antibody treatment. The establishment of novel prognostic scores for NLPHL patients may optimize risk group and treatment allocation in newly diagnosed and relapsed disease.https://www.mdpi.com/2072-6694/15/13/3310nodular lymphocyte-predominant Hodgkin lymphomaB-NHLradiotherapychemotherapyanti-CD20 antibody treatmenthistopathological growth pattern |
| spellingShingle | Dennis A. Eichenauer Michael Fuchs Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go? Cancers nodular lymphocyte-predominant Hodgkin lymphoma B-NHL radiotherapy chemotherapy anti-CD20 antibody treatment histopathological growth pattern |
| title | Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go? |
| title_full | Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go? |
| title_fullStr | Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go? |
| title_full_unstemmed | Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go? |
| title_short | Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go? |
| title_sort | treatment of nodular lymphocyte predominant hodgkin lymphoma where do we stand where do we go |
| topic | nodular lymphocyte-predominant Hodgkin lymphoma B-NHL radiotherapy chemotherapy anti-CD20 antibody treatment histopathological growth pattern |
| url | https://www.mdpi.com/2072-6694/15/13/3310 |
| work_keys_str_mv | AT dennisaeichenauer treatmentofnodularlymphocytepredominanthodgkinlymphomawheredowestandwheredowego AT michaelfuchs treatmentofnodularlymphocytepredominanthodgkinlymphomawheredowestandwheredowego |